Tramadol

Ultram | ConZip

FDA ApprovedAnalgesicsOpioid Analgesics
Half-life: Approximately 6-7 hoursPregnancy: Category C

Overview

Tramadol is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake inhibition, used for moderate to moderately severe pain.

Indications

  • Moderate to moderately severe pain

Contraindications

  • Significant respiratory depression
  • Acute intoxication with alcohol or CNS depressants
  • Children under 12 years
  • Concurrent or recent use of monoamine oxidase inhibitors

Classification

Mechanism of Action

Binds weakly to mu-opioid receptors and inhibits reuptake of serotonin and norepinephrine. Its active metabolite O-desmethyltramadol has substantially greater mu-opioid affinity.

Pharmacodynamics

Provides analgesia through combined opioid and monoaminergic mechanisms. Its analgesic efficacy depends in part on CYP2D6-mediated conversion to the active metabolite.

Pharmacokinetics

Absorption
Well absorbed orally with high bioavailability.
Distribution
Widely distributed with moderate protein binding.
Metabolism
Metabolized in the liver by CYP2D6 and CYP3A4 to active and inactive metabolites.
Excretion
Excreted mainly in urine as metabolites.
Half-life
Approximately 6-7 hours
Bioavailability
Approximately 70% (rising with repeated dosing)
Protein Binding
Approximately 20%

Dosage

Typical dosage: 50-100 mg every 4-6 hours as needed; maximum 400 mg per day

Available Forms

  • Tablet
  • Extended-release tablet
  • Capsule

Side Effects

Common

  • Nausea
  • Dizziness
  • Constipation
  • Headache
  • Somnolence

Serious

  • Respiratory depression
  • Seizures
  • Serotonin syndrome

Rare

  • Anaphylaxis

Drug Interactions

Combined serotonergic activity increases the risk of serotonin syndrome.

Carbamazepinemoderate

Induces tramadol metabolism, reducing analgesic effect and increasing seizure potential.

Warnings

⚠️BLACK BOX WARNING

Tramadol carries risks of addiction, abuse, and misuse; life-threatening respiratory depression; and neonatal opioid withdrawal syndrome with prolonged use in pregnancy. Ultra-rapid CYP2D6 metabolizers and children are at particular risk of respiratory depression. Concomitant use with benzodiazepines or other CNS depressants can be fatal.

Pregnancy

Category C

Toxicity

Overdose can cause CNS and respiratory depression, seizures, and serotonin syndrome.

Overdose

Support ventilation; naloxone can reverse respiratory depression but may increase seizure risk. Manage seizures with benzodiazepines.

References

Looking for patient-friendly information? Visit RemedyDoor for easy-to-read guides about this medication.